Levina (Ethinylestradiol, Levonorgestrel)

The estrogen component, ethinylestradiol, suppresses the release of follicle‑stimulating hormone, while the progestin component, levonorgestrel, blocks the luteinizing hormone surge needed for ovulation. Together they also thicken cervical mucus and alter the uterine lining, creating multiple barriers to fertilisation and implantation.

The dosing regimen for Levina is determined by the prescribing clinician. Typically, it is taken once daily at the same time each day, but the exact schedule, tablet strength and cycle length are set according to individual medical assessment.

Levina is not intended for use during an existing pregnancy and should be stopped if pregnancy occurs. While limited data exist for breastfeeding, most guidelines advise caution; women should discuss potential risks and benefits with their healthcare provider before using it while nursing.

To order Levina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levina contains the widely used estrogen‑progestin pair ethinylestradiol and levonorgestrel, offering efficacy comparable to other second‑generation combined pills. Its safety profile, dosing convenience and extensive clinical experience make it a standard option alongside alternatives that may use different progestins or estrogen doses.

Levina tablets should be stored at ambient temperature, below 25 °C, in their original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Levina is taken orally, usually one tablet each day, preferably at the same time each day. It is part of a 21‑day active tablet regimen followed by a hormone‑free interval, but the exact schedule is defined by the prescriber.

Serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare but severe allergic reactions and liver tumours have also been reported. Users should seek immediate medical attention if they experience unexplained leg pain, chest discomfort, severe headache, or signs of an allergic reaction.

Levina is contraindicated in women with a history of blood‑clotting disorders, uncontrolled hypertension, certain cancers, active liver disease, or known hypersensitivity to any component. It should also be avoided by smokers over 35 years of age and by anyone taking strong CYP3A4‑inducing medications without additional contraceptive protection.